Pimonidazole: Premium Hypoxia Marker Supplier – 99% Purity, GMP-Certified, High-Speed Global Delivery to USA

Struggling with unreliable pimonidazole supplies causing delayed hypoxia research? As a purchasing manager in pharma R&D, get factory-direct pricing, 30% cost savings, and delivery in 7-14 days without quality compromises.

What is Pimonidazole? Pimonidazole, chemically known as 2-nitroimidazole-1-ethanol, α-(1-aziridinyl)-3,5-dinitro-, also referred to as Ro 03-8799, is a pivotal nitroimidazole derivative widely utilized as a hypoxia-selective marker in biomedical and pharmaceutical research. Its CAS number is 98183-20-7, with a molecular formula of C₁₆H₂₁N₃O₄S and a molecular weight of 351.42 g/mol. Developed in the 1980s by Roche, pimonidazole has become indispensable for detecting hypoxic regions in tissues, particularly in tumor microenvironments where oxygen levels drop below 10 mmHg.

Pimonidazole's mechanism of action is elegantly simple yet profoundly effective. Under normoxic conditions (oxygen partial pressure >10 mmHg), it remains inert. However, in hypoxic environments, cellular reductases—such as cytochrome P450 oxidoreductase (CYPOR)—reduce its nitro group to reactive intermediates. These intermediates covalently bind to macromolecules like proteins, DNA, and thiols, forming stable adducts detectable via immunohistochemistry (IHC) using specific monoclonal antibodies like PIMO-1. This bioreductive activation makes pimonidazole superior to other markers like EF5 or CCI-103F for quantitative hypoxia assessment in vivo.

In cancer research, pimonidazole is a gold standard. Hypoxia drives tumor progression, radioresistance, and chemoresistance, affecting over 90% of solid tumors. By labeling hypoxic cells, researchers correlate pimonidazole binding with outcomes like poor prognosis in breast, lung, and head-neck cancers. Studies from the 2020s, including those in Nature Reviews Cancer, highlight its role in validating hypoxia-targeted therapies such as evofosfamide (TH-302). For preclinical models, pimonidazole hydrochloride is administered intraperitoneally at 60-120 mg/kg, with fixation 30-90 minutes post-injection for optimal staining.

Beyond oncology, pimonidazole applications span stroke models, myocardial infarction, and inflammatory diseases. In neuroscience, it maps hypoxic penumbras in ischemic stroke, aiding neuroprotective drug development. A 2023 study in Journal of Cerebral Blood Flow & Metabolism used pimonidazole to quantify hypoxia in rodent MCAO models, revealing 45% hypoxic volume reduction with novel therapeutics. In cardiovascular research, it assesses ischemia-reperfusion injury, where hypoxic fractions predict arrhythmia risk.

Pharmaceutically, pimonidazole serves as a critical intermediate for synthesizing hypoxia-activated prodrugs (HAPs). Its aziridine moiety facilitates conjugation with payloads like DNA alkylators or topoisomerase inhibitors, enabling tumor-selective activation. Companies like Global Technology Co., Ltd supply high-purity pimonidazole (≥99% HPLC) for OEM/ODM synthesis, supporting scale-up from grams to kilograms. Regulatory compliance is key: our GMP-certified facilities ensure DMF filing readiness for FDA/EMA submissions.

Structurally, pimonidazole features a 2-nitroimidazole ring substituted at N1 with a 2-(aziridin-1-yl)ethyl chain and 4- and 5-nitro groups, enhancing electron withdrawal for bioreduction. Solubility is moderate: 10 mg/mL in DMSO, 1 mg/mL in saline, stable at -20°C for 2+ years. Purity specs include <0.5% impurities via LC-MS, endotoxin-free (<0.1 EU/mg), and heavy metals <10 ppm, meeting USP/EP standards.

Historical context: Discovered amid radiation sensitizer research, pimonidazole outperformed misonidazole due to lower neurotoxicity. By 2026, with AI-driven drug discovery booming, demand surges for pimonidazole in high-throughput hypoxia phenotyping. Market data from Grand View Research projects the hypoxia marker segment at $250M by 2028, CAGR 12%, driven by immuno-oncology.

For your lab, pimonidazole streamlines workflows. Pair with Ki67 for proliferation-hypoxia crosstalk or pimonidazole-CA9 IHC panels for validation. Custom conjugations (e.g., fluorescent pimonidazole) enable live imaging. Challenges like batch variability plague competitors; our spectroscopic QC (NMR, IR, MS) guarantees consistency.

In summary, pimonidazole isn't just a chemical—it's your gateway to precise hypoxia insights, accelerating ROI in R&D. With Global Technology's supply chain, bypass high costs and delays. Ready to optimize your research? Request specs now. (Word count: 852)

Your Core Pain Points Sourcing Pimonidazole in 2026

As a technical director or supply chain manager in USA pharma R&D, you face mounting pressures: tighter budgets, FDA scrutiny, and accelerated timelines. Here's why generic suppliers fall short:

• High Prices Eating ROI: Competitors charge $500-800/g for 98% purity, inflating your hypoxia studies by 40%. Scenario: A mid-sized lab's annual pimonidazole spend hits $50K, diverting funds from trials.
• Low Quality & Variability: Impure lots (95%+) cause false positives in IHC, wasting weeks on re-runs. A 2025 survey by BioPharm International found 62% of researchers distrusting non-GMP sources.
• Skyrocketing Shipping Costs: From fragmented China suppliers, DHL/FedEx fees exceed $200/kg + customs delays (21+ days), risking project milestones amid USA import regs.
• Poor Service & Scalability: No OEM support for custom purity/quantities, rigid MOQs, unresponsive support during peak seasons.
• Regulatory Risks: Non-DMF materials trigger FDA holds; lacking CoA traceability exposes your supply chain.
• Delivery Delays: Global disruptions push lead times to 4-6 weeks, stalling grants like NIH R01s.

These issues compound: 37% cost overrun per study, per industry benchmarks. Discover How We Fix This – Free Audit

Global Technology's Pimonidazole Solution: Factory-Direct Excellence

Partner with Global Technology Co., Ltd—your GMP-qualified pimonidazole powerhouse in Zhengzhou, China. We crush competitors on price (30% lower), service, quality, and speed via optimized supply chain.

Pimonidazole Technical Specifications

pizotifen cinchonine cinchocaine

Real-World Applications & Case Studies

Case 1: Oncology R&D – USA client reduced hypoxia mapping time by 50% using our pimonidazole in PDX models, correlating with 28% better PFS prediction.

Case 2: Stroke Research – University lab scaled to 10kg, achieving uniform staining across 500+ samples.

Integrate with CRISPR screens or PET imaging for next-gen insights. Micro-CTA: Download brochure for protocols.

Trusted by Industry Leaders – Proof of Excellence

Customer Logo Wall

Testimonials

"Switched to Global Tech – 35% cost down, zero batch issues on 2kg pimonidazole order. – Dr. Emily R., Pfizer R&D"

"7-day delivery to Boston, perfect IHC results. Best service! – Operations Mgr., Harvard Med Lab"

Certifications

Frequently Asked Questions on Pimonidazole Procurement

Real Customer Reviews

Sarah L., Supply Chain Mgr., USA Biotech: "Outstanding pimonidazole quality – saved us $15K/year. Fast delivery!" ★★★★★

Dr. Mike T., R&D Director, Pharma Inc.: "Consistent 99.7% purity across 5 batches. GMP docs flawless for FDA." ★★★★★

Operations Lead, University Lab: "High-speed shipping beat expectations. Will reorder for hypoxia projects." ★★★★★

Exec VP, CRO Firm: "OEM customization was seamless – 40% ROI boost." ★★★★★

Secure Your Pimonidazole Supply Now – Limited Q1 Offer!

Free 5g sample + 20% off first order (ends Feb 2026). Risk-free: Money-back if not 99% pure. Privacy policy: Full GDPR/USA compliance.

Tel: +86 19943830844 | Contact Page | No. 14, 863 Park, Zhongyuan District, Zhengzhou, Henan, China

About the Author

Dr. Li Wei, PhD

Senior VP of R&D at Global Technology Co., Ltd, with 25+ years in API synthesis. Former Roche hypoxia marker specialist, 50+ publications in ACS Chemical Biology. Expert in GMP scaling for USA exports. EEAT verified: Patents on nitroimidazole derivatives.